Atherosclerosis
Volume 182, Issue 1 , Pages 71-77 , September 2005

A novel thiazolidinedione MCC-555 down-regulates tumor necrosis factor-α-induced expression of vascular cell adhesion molecule-1 in vascular endothelial cells

  • Shogo Kurebayashi

      Affiliations

    • Department of Molecular Medicine, Osaka University Graduate School of Medicine (C-4), 2-2 Yamada-oka, Suita-city, Osaka 565-0871, Japan
    • These two authors equally contributed to this work.
    • ,
  • Xin Xu

      Affiliations

    • Department of Molecular Medicine, Osaka University Graduate School of Medicine (C-4), 2-2 Yamada-oka, Suita-city, Osaka 565-0871, Japan
    • These two authors equally contributed to this work.
    • ,
  • Shinichi Ishii

      Affiliations

    • Research Laboratory II, Mitsubishi Pharma Corporation, Yokohama, Japan
    • ,
  • Muneshige Shiraishi

      Affiliations

    • Research Laboratory II, Mitsubishi Pharma Corporation, Yokohama, Japan
    • ,
  • Haruhiko Kouhara

      Affiliations

    • Department of Molecular Medicine, Osaka University Graduate School of Medicine (C-4), 2-2 Yamada-oka, Suita-city, Osaka 565-0871, Japan
    • ,
  • Soji Kasayama

      Affiliations

    • Department of Molecular Medicine, Osaka University Graduate School of Medicine (C-4), 2-2 Yamada-oka, Suita-city, Osaka 565-0871, Japan
    • Corresponding Author InformationCorresponding author. Tel.: +81 6 6879 3837; fax: +81 6 6879 3839.

Received 8 August 2004 ,Revised 23 December 2004 ,Accepted 8 February 2005.

References 

  1. Lehmann JM, Moore LB, Smith-Oliver TA, et al. An anti-diabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor γ (PPARγ). J Biol Chem. 1995;270:12953–12956
  2. Dreyer C, Krey G, Keller H, et al. Control of the peroxisomal beta-oxidation pathway by a novel family of nuclear hormone receptors. Cell. 1992;68:879–887
  3. Willson TM, Cobb JE, Cowan DJ, et al. The structure–activity relationship between peroxisome proliferator-activated receptor gamma agonism and the anti-hyperglycemic activity of thiazolidinediones. J Med Chem. 1996;39:665–668
  4. Jiang C, Ting AT, Seed B. PPAR-γ agonists inhibit production of monocyte inflammatory cytokines. Nature. 1998;391:82–86
  5. Ricote M, Li AC, Willson TM, Kelly CJ, Glass CK. The peroxisome proliferator-activated receptor-γ is a negative regulator of macrophage activation. Nature. 1998;391:79–82
  6. Marx N, Schonbeck U, Lazar MA, Libby P, Plutzky J. Peroxisome proliferator-activated receptor gamma activators inhibit gene expression and migration in human vascular smooth muscle cells. Circ Res. 1998;83:1097–1103
  7. Murao K, Imachi H, Momoi A, et al. Thiazolidinedione inhibits the production of monocyte chemoattractant protein-1 in cytokine-treated human vascular endothelial cells. FEBS Lett. 1999;454:27–30
  8. Jackson SM, Parhami F, Xi XP, et al. Peroxisome proliferator-activated receptor–activators target human endothelial cells to inhibit leukocyte-endothelial cell interaction. Arterioscler Thromb Vasc Biol. 1999;19:2094–2104
  9. Minamikawa J, Tanaka S, Yamauchi M, Inoue D, Koshiyama H. Potent inhibitory effect of troglitazone on carotid arterial wall thickness in type 2 diabetes. J Clin Endocrinol Metab. 1998;83:1818–1820
  10. Cybulsky MI, Gimbrone MA. Endothelial expression of a mononuclear leukocyte adhesion molecule during atherogenesis. Science. 1991;251:788–791
  11. Bevilacqua MP, Nelson RM, Mannori G, Cecconi O. Endothelial-leukocyte adhesion molecules in human disease. Annu Rev Med. 1994;45:361–378
  12. Cybulsky MI, Iiyama K, Li H, et al. A major role for VCAM-1, but not ICAM-1, in early atherosclerosis. J Clin Invest. 2001;107:1255–1262
  13. Caulin-Glaser T, Watson CA, Pardi R, Bender JR. Effects of 17β-estradiol on cytokine-induced endothelial cell adhesion molecule expression. J Clin Invest. 1996;98:36–42
  14. Otsuki M, Saito H, Xu X, et al. Progesterone, but not medroxyprogesterone, inhibits vascular cell adhesion molecule-1 expression in human vascular endothelial cells. Arterioscl Thromb Vasc Biol. 2001;21:243–248
  15. Gille J, Paxton LLL, Lawley TJ, Caughman SW, Swerlick RA. Retinoic acid inhibits the regulated expression of vascular cell adhesion molecule-1 by cultured dermal microvascular endothelial cells. J Clin Invest. 1997;99:492–500
  16. Marx N, Sukhova GK, Collins T, Libby P, Plutzky J. PPARα activators inhibit cytokine-induced vascular cell adhesion molecule-1 expression in human endothelial cells. Circulation. 1999;99:3125–3131
  17. Xu X, Otsuki M, Saito H, et al. PPARα and GR differentially down-regulate the expression of nuclear factor-κB-responsive genes in vascular endothelial cells. Endocrinology. 2001;142:3332–3339
  18. Upton R, Widdowson PS, Ishii S, Tanaka H, Williams G. Improved metabolic status and insulin sensitivity in obese fatty (fa/fa) Zucker rats and Zucker Diabetic Fatty (ZDF) rats treated with the thiazolidinedione MCC-555. Br J Pharmacol. 1998;125:1708–1714
  19. Pickavance L, Widdowson PS, King P, et al. The development of overt diabetes in young Zucker Diabetic Fatty (ZDF) rats and the effects of chronic MCC-555 treatment. Br J Pharacol. 1998;125:767–770
  20. Reginato MJ, Bailey ST, Krakow SL, et al. A potent anti-diabetic thiazolidinedione with unique peroxisome proliferator-activated receptor gamma-activating properties. J Biol Chem. 1998;273:32679–32684
  21. Ishii S, Shiraishi M, Sasaki K, Kawai M. A novel PPAR agonist, MCC-555, ameliorates endothelial cell dysfunction. In: Second International Symposium on PPARs: From Basic Science to Clinical Applications. Florence, Italy. March 19–22, 2003 (Abstract);
  22. Willson TM, Brown PJ, Sternbach DD, Henke BR. The PPARs: from orphan receptors to drug discovery. J Med Chem. 2000;43:527–550
  23. De Caterina R, Libby P, Peng HB, et al. Nitric oxide decreases cytokine-induced endothelial activation. Nitric oxide selectively reduces endothelial expression of adhesion molecules and proinflammatory cytokines. J Clin Invest. 1995;96:60–68
  24. Goya K, Otsuki M, Xu X, Kasayama S. Effects of the prostaglandin I2 analogue, beraprost sodium, on vascular cell adhesion molecule-1 expression in human vascular endothelial cells and circulating vascular cell adhesion molecule-1 level in patients with type 2 diabetes mellitus. Metabolism. 2003;52:192–198
  25. Takagi M, Kasayama S, Yamamoto T, et al. Advanced glycation endproducts stimulate interleukin-6 production by human bone-derived cells. J Bone Miner Res. 1997;12:439–446
  26. Neish AS, Williams AJ, Palmer HJ, Whitley MZ, Collins T. Functional analysis of the human vascular cell adhesion molecule-1 promoter. J Exp Med. 1992;176:1583–1593
  27. Staels B, Dallongeville J, Auwerx J, et al. Mechanism of action of fibrates on lipid and lipoprotein metabolism. Circulation. 1998;98:2088–2093
  28. Oliver WR, Shenk JL, Snaith MR, et al. A selective peroxisome proliferator-activated receptor δ agonist promotes reverse cholesterol transport. Proc Natl Acad Sci USA. 2001;98:5306–5311
  29. Rival Y, Beneteau N, Taillandier T, et al. PPARα and PPARδ activators inhibit cytokine-induced nuclear translocation of NF-κB and expression of VCAM-1 in EAhy926 endothelial cells. Eur J Pharmacol. 2002;435:143–151
  30. Gaede P, Vedel P, Larsen N, et al. Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med. 2003;348:383–393

PII: S0021-9150(05)00123-1

doi: 10.1016/j.atherosclerosis.2005.02.004

Atherosclerosis
Volume 182, Issue 1 , Pages 71-77 , September 2005

Article Tools

* Image Usage & Resolution